These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20195905)

  • 1. Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
    Wyrwich KW; Mody R; Larsen LM; Lee M; Harnam N; Revicki DA
    Qual Life Res; 2010 May; 19(4):551-64. PubMed ID: 20195905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexlansoprazole for the treatment of esophagitis and GERD.
    Davies SL
    Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders.
    Rentz AM; Kahrilas P; Stanghellini V; Tack J; Talley NJ; de la Loge C; Trudeau E; Dubois D; Revicki DA
    Qual Life Res; 2004 Dec; 13(10):1737-49. PubMed ID: 15651544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
    Croxtall JD; Scott LJ
    Drugs; 2010 Aug; 70(12):1593-601. PubMed ID: 20687622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
    Gremse D; Gold BD; Pilmer B; Hunt B; Korczowski B; Perez MC
    Dig Dis Sci; 2019 Feb; 64(2):493-502. PubMed ID: 30390234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
    Abel C; Desilets AR; Willett K
    Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole.
    Kovacs TO; Freston JW; Haber MM; Atkinson S; Hunt B; Peura DA
    Dig Dis Sci; 2010 May; 55(5):1325-36. PubMed ID: 19582579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.
    Metz DC; Pilmer BL; Han C; Perez MC
    Am J Gastroenterol; 2011 Nov; 106(11):1953-60. PubMed ID: 21844923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL.
    de la Loge C; Trudeau E; Marquis P; Kahrilas P; Stanghellini V; Talley NJ; Tack J; Revicki DA; Rentz AM; Dubois D
    Qual Life Res; 2004 Dec; 13(10):1751-62. PubMed ID: 15651545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
    Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
    Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
    Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders.
    Revicki DA; Rentz AM; Tack J; Stanghellini V; Talley NJ; Kahrilas P; De La Loge C; Trudeau E; Dubois D
    Clin Gastroenterol Hepatol; 2004 Sep; 2(9):769-77. PubMed ID: 15354277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V; Ferry G; Gunasekaran T; Huang B; Keith R; Book L
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S308-18. PubMed ID: 12607791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
    Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
    Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
    Hongo M; Miwa H; Kusano M;
    J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
    Howden CW; Larsen LM; Perez MC; Palmer R; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(9):895-907. PubMed ID: 19681809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.